explore -WSS

explore

author：leisure time 2025-10-02 22:24:05 - browse：45684

Photography of the US department of health and human services in Silver Spring MD — Manuel Balce Ceneta/AP

An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

Triple-check your data or we’ll reject your device, the FDA warned.

The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： HHS leader on health, climate change and biopharma emissions

leisure time

focus

WSS

Precocious puberty in girls comes with mental health risks

HHS leader on health, climate change and biopharma emissions

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

First medicine developed to treat MASH expected to be approved soon

Change Healthcare cyberattack prompts Medicare loan program

entertainment

explore

leisure time

Heart attack and stroke risk calculators need revising

The problem with charging patients to message their doctors

Malaria cases in Florida and Texas: Here’s what you need to know

The EU Joint Clinical Assessment needs to live up to its promise

Tori Bowie and the unacceptable rates of Black maternal death

2023 STAT Wunderkinds: get to know the winners

Affirmative action in medical school literally saved lives

Precocious puberty in girls comes with mental health risks

What does generative AI mean for health care? We asked experts

Amylyx ALS drug fails large clinical trial

focus

The Readout: Amylyx, Alumis, and Lundbeck drug updates

NIH confirmation hearing shows politicization of research

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Lawmakers consider Medicare pay reforms for doctors

STAT Summit: Michael J. Fox on progress in Parkinson's research

Solve the antibiotic resistance crisis with preventive drugs

entertainment

leisure time

focus

entertainment